ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
PRO-101, the Phase 1b study of prosetin in ALS participants, is fully enrolled Prosetin is safe and well-tolerated over long-term dosing at target active exposures in ALS participants, and demonstrates exposure-related, statistically significant target engagement Data will be presented at...
PRO-101, the Phase 1b study of prosetin in ALS participants, is fully enrolled Prosetin is safe and well-tolerated over long-term dosing at target active exposures in ALS participants, and demonstrates exposure-related, statistically significant target engagement Data will be presented at...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.